Table 7. Patient ACT 95387.
| HLA | Epitope location | HXB2 epitope sequence (MHC IC50) | Sampling dates after primary infection (% of RT UDPS variants) | ||||
| 4.5 months | 5.5 months | 5.5 months | 17.5 months | 29.5 months | |||
| RNA | RNA | DNA | RNA | RNA | |||
| A*03:01 | p17 | KIRLRPGGK | Id | Id | Id | Id | Id |
| (18–26) | (181.36) | ||||||
| p17 | RLRPGGKKK | Id | Id | Id | RLRPGGKKQ | RLRPGGKKQ | |
| (20–28) | (212.83) | (17483.36) | (17483.36) | ||||
| RT | ALVEICTEMEK | ALVEICTEMEK | ALVEICTEMEK | ALVEICTEMEK | ALVEICTEMEK | ALVEICTEMEK | |
| (33–43) | (313.24) | (67%) (313.24) | (100%) | (97%) | (100%) | (96%) | |
| ALTEICTEMEK | (313.24) | (313.24) | (313.24) | (313.24) | |||
| (25%) (351.63) | KLVEICTEIER | ALVEICTEMEE | |||||
| ALIEICTEMEK | (3%) | (4%) | |||||
| (8%) (165.44) | (2238.39) | (32546.12) | |||||
| RT | KLVDFRELNK | KLVDFRELNK | ND | KLVDFRELNK | KLVDFRELNK | KLVDFRELNK | |
| (73–82) | (36.70) | (100%) | (80%) (36.70) | (96%) (36.70) | (100%) | ||
| (36.70) | KLVDFKELNK | KLVDLGELNK | (36.70) | ||||
| (20%) (64.06) | (4%) (80.05) | ||||||
| RT | GIPHPAGLK | GIPHPAGLK | ND | GIPHPAGLK | GIPHPAGLK | GIPHPAGLK | |
| (93–101) | (316.17) | (100%) | (100%) | (100%) | (96%) (316.17) | ||
| (316.17) | (316.17) | (316.17) | GIPHLAGLK | ||||
| (4%) (556.37) | |||||||
| RT | AIFQSSMTK | AIFQSSMTK | AIFQSSMTK | AIFQSSMTK | AIFQSSMTK | AIFQSSMTK | |
| (158–166) | (12.74) | (64%) (12.74) | (100%) | (96%) | (97%) | (99%) | |
| AIFQASMTK | (12.74) | (12.74) | (12.74) | (12.74) | |||
| (23%) (20.85) | AIFQSNMTK | AIYQSSMTK | AIFQINMTK | ||||
| AIFQCSMTK | (4%) | (3%) | (1%) | ||||
| (7%) (13.50) | (18.21) | (9.20) | (21.64) | ||||
| AIFQGSMTK | |||||||
| (2.5%) (18.30) | |||||||
| AIFQTSMTK | |||||||
| (2.5%) (20.04) | |||||||
| NEF | AVDLSHFLK | ALDLSHFLR | ALDLSHFLR | ALDLSHFLR | ALDLSHFLR | ALDLSHFLR | |
| (66–97) | (245.36) | (1944.13) | (1944.13) | (1944.13) | (1944.13) | (1944.13) | |
| A*30:02 | p17 | RSLYNTVATLY | KSLYNTVATLY | KSLYNTVATLY | KSLYNTVATLY | KSLYNTVATLY | KSLYNTVATLY |
| (76–86) | (17.71) | (18.12) | (18.12) | (18.12) | (18.12) | (18.12) | |
| RT | KQNPDIVIY | KQNPDIVIY | ND | KQNPDIVIY | KQNPDIVIY | KQNPDIVIY | |
| (173–181) | (56.89) | (12%) (56.89) | (4%) | (60%) | (60%) | ||
| KQHPDIVIY | (56.89) | (56.89) | (56.89) | ||||
| (45%) (70.32) | KQYPDIVIY | KQHPDIVIY | KQHPDIVIY | ||||
| KQNPDIDIY | (56%) | (40%) | (40%) | ||||
| (26%) (74.12) | (77.92) | (70.32) | (70.32) | ||||
| KQYPNIVIY | KQHPDIVIY | ||||||
| (8%) (57.29) | (40%) | ||||||
| KQYPDIVIY | (70.32) | ||||||
| (5%) (77.92) | |||||||
| KQNQDIVIY | |||||||
| (3%) (74.97) | |||||||
| B*07:02 | p24 | SPRTLNAWV | SPRTFNAWV | Id | Id | Id | Id |
| (16–24) | (25.64) | (28.93) | |||||
| p24 | GPGHKARVL | Id | Id | Id | Id | Id | |
| (223–231) | (97.86) | ||||||
| NEF | FPVTPQVPL | FPVRPQVPL | FPVRPQVPL | FPVRPQVPL | FPVRPQVPL | FPVRPQVPL | |
| (68–76) | (11.70) | (7.48) | (7.48) | (7.48) | (7.48) | (7.48) | |
| NEF | TPQVPLRPM | RPQVPLRPM | RPQVPLRPM | RPQVPLRPM | RPQVPLRPM | RPQVPLRPM | |
| (71–79) | (12.45) | (3.68) | (3.68) | (3.68) | (3.68) | (3.68) | |
| NEF | RPMTYKAAL | RPMTFKGAL | RPMTFKGAL | RPMTFKGAL | RPMTFKGAL | RPMTFKGAL | |
| (77–85) | (2.67) | (2.51) | (2.51) | (2.51) | (2.51) | (2.51) | |